^
Association details:
| Biomarker: | KRAS G13D |
|---|---|
| Cancer: | Colorectal Cancer |
| Drug: | ompenaclid (RGX-202) (SLC6A8 inhibitor) |
| Direction: | Sensitive |
Evidence:
Source:
Title:
Phase I monotherapy dose escalation of RGX-202, a first-in-class oral inhibitor of the SLC6a8/CKB pathway, in patients with advanced gastrointestinal (GI) solid tumors.
Published date:
05/13/2020
Excerpt:
At the highest dose, 2 of 3 CRC pts had prolonged disease control: a patient with a KRAS G13D mutant cancer had SD for 14 weeks; and a patient with KRAS G12V mutant (MSS) cancer had a confirmed PR ongoing at 30 weeks.
DOI:
10.1200/JCO.2020.38.15_suppl.3504
Trial ID:
